Page 7 - Fast Track Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moleculin Biotech (MBRX) Announces Publication of Data from Successful European Phase 1 Trial of Annamycin

Moleculin Biotech (MBRX) Announces Publication of Data from Successful European Phase 1 Trial of Annamycin
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomWolfram dempke moleculinPriebe moleculinLiposomal annamycinJohn paul waymack moleculinWalter klempJenene thomasBritish journal of cancer researchExchange commissionDrug administrationSecurities exchangeMoleculin biotech incMoleculin biotechAfter induction therapyBritish journalEuropean chief medical officer

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United kingdomUnited statesJenene thomasWalter klempJohn paul waymack moleculinLiposomal annamycinPriebe moleculinWolfram dempke moleculinExchange commissionDrug administrationSecurities exchangeBritish journal of cancer researchMoleculin biotech incBritish journalMoleculin biotechAfter induction therapy

Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesAlan mendelsohnAdam daleyJohn koconisJoyce mc tengSecurities exchangeSociety for pediatric dermatology annual meetingTimber pharmaceuticals incStanford universityDrug administrationCompany annual report on formBerry company public relationsExchange commissionPediatric dermatologyAnnual meeting

Timber Pharmaceuticals (TMBR) to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Timber Pharmaceuticals (TMBR) to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesJoyce mc tengAlan mendelsohnStanford universitySociety for pediatric dermatology annual meetingTimber pharmaceuticals incDrug administrationTimber pharmaceuticalsPediatric dermatologyAnnual meetingChief medical officerGlobal assessmentMaximal use studyBreakthrough therapy designationFast track status

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAdam daleyJohn koconisBerry company public relationsCompany annual report on formSecurities exchangeDrug administrationExchange commissionTimber pharmaceuticals incChief executive officerOrphan products grantBreakthrough therapy designationFast track statusTimber pharmaceuticalsSecurities actSecurities exchange act